Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Micro-scale dosimetry comparison of prostate-specific membrane antigen vs dual-targeting prostate-specific membrane antigen-albumin radiopharmaceuticals for treatment of metastatic prostate cancer.
FY 2024-25
Summary
Prostate cancer accounts for 22% of Canadian cancer diagnoses in men. When prostate cancer metastasizes throughout the body, it becomes increasingly harder to treat with external radiation therapy. This work aims to improve the understanding of novel radiopharmaceutical (RP) therapies for the treatment of metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is a cell receptor with over-expression in prostate cancer making it a promising target for treatment. RP therapies are composed of a targeting ligand, such as PSMA, linked to a radioactive compound that are injected into the body. PSMA targeting can deliver radiation dose to cancerous cells expressing the receptor while avoiding healthy tissues. A challenge with PSMA RPs is that many patients are not receiving high enough radiation dose to cancer cells to eradicate the metastases or primary tumors. Modifying PSMA RPs to bind to albumin, a protein found at high levels in the blood, can increase blood circulation time of the RP, increasing the amount of RP that will reach metastases, bind to PSMA receptors, and deliver radioactive dose. Unfortunately, these modifications to PSMA RPs have the potential to increase dose to healthy organs, particularly the kidneys. This study will compare the distribution of PSMA binding and dual PSMA-albumin binding RPs at the sub-organ level in both tumor and healthy organ tissue using a mouse model for prostate cancer and novel imaging procedures. The findings of this research will impact future treatment efficacy as dual-binding RPs have the potential to improve outcomes of patients with metastatic prostate cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530300
Name
Martin Isabella V
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Prcname2
Special Cases - Awards Programs
Projecttitle
Micro-scale dosimetry comparison of prostate-specific membrane antigen vs dual-targeting prostate-specific membrane antigen-albumin radiopharmaceuticals for treatment of metastatic prostate cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Albumin; Image Processing; Ionizing-Radiation Quantum Imaging Detector (Iqid Camera); Microdosimetry; Nuclear Medicine; Prostate Cancer; Prostate Specific Membrane Antigen (Psma); Radiation Therapy; Radiopharmaceutical Therapy; Theranostics
Abstract
Prostate cancer accounts for 22% of Canadian cancer diagnoses in men. When prostate cancer metastasizes throughout the body, it becomes increasingly harder to treat with external radiation therapy. This work aims to improve the understanding of novel radiopharmaceutical (RP) therapies for the treatment of metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is a cell receptor with over-expression in prostate cancer making it a promising target for treatment. RP therapies are composed of a targeting ligand, such as PSMA, linked to a radioactive compound that are injected into the body. PSMA targeting can deliver radiation dose to cancerous cells expressing the receptor while avoiding healthy tissues. A challenge with PSMA RPs is that many patients are not receiving high enough radiation dose to cancer cells to eradicate the metastases or primary tumors. Modifying PSMA RPs to bind to albumin, a protein found at high levels in the blood, can increase blood circulation time of the RP, increasing the amount of RP that will reach metastases, bind to PSMA receptors, and deliver radioactive dose. Unfortunately, these modifications to PSMA RPs have the potential to increase dose to healthy organs, particularly the kidneys. This study will compare the distribution of PSMA binding and dual PSMA-albumin binding RPs at the sub-organ level in both tumor and healthy organ tissue using a mouse model for prostate cancer and novel imaging procedures. The findings of this research will impact future treatment efficacy as dual-binding RPs have the potential to improve outcomes of patients with metastatic prostate cancer.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Martin, Isabella V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~